Electronic Lab Notebook Market

How big is Electronic Lab Notebook Market in 2026?

Assessed at USD 586.0 million in 2025 and progressing to USD 624.1 million in 2026, the electronic lab notebook market valuation is on course to reach USD 1,171.5 million by 2036, supported by a forecast-period CAGR of 6.5%.

The global electronic lab notebook market was valued at USD 586.0 million in 2025 and reaches USD 624.1 million in 2026. FMI research indicates that total industry valuation will hit USD 1,171.5 million by 2036, expanding at a 6.5% CAGR. Whereas multi-omics sequence analysis tools expand at a faster 12.0% CAGR, electronic lab notebooks progress steadier under multi-year seat licensing. Within functional scope, cross-disciplinary enterprise R&D ELN platforms will claim 57.1% share in 2026. The demand for digital notebooks is supported by R&D teams replacing disconnected paper binders and spreadsheets across pharmaceutical labs. According to a January 2026 Sapio Sciences survey of 150 scientists, 65% repeated experiments due to inaccessible prior records. Pharmaceutical IT buyers therefore standardize enterprise scientific data platforms across global discovery sites. However, legacy instrument data parsing and rigid template setups still slow bench scientist onboarding.

Key Market Trends & Insights

• By functional scope: Based on functional scope, cross-disciplinary enterprise R&D ELN systems will claim 57.1% during 2026 via unified chemistry and biologics schemas.
• By deployment model: By deployment model, cloud-native SaaS architectures command an estimated 68.7% during 2026 through elastic storage and vendor validation.
• By license model: In 2026, named-seat annual enterprise subscriptions are expected to lead license model with 76.3% share under predictable software agreements.
• By end-use industry: By end-use industry, biopharmaceutical, CRO and biotech R&D accounts generate a forecast 53.9% during 2026 owing to Part 11 mandates.
• By workflow integration: LIMS and instrument data-capture integrated ELN deployments secure an anticipated 64.2% of workflow integration during 2026 via automated balance capture.

Regional Highlights

• Notable national progression: South Korea advances on 7.6% compound annual growth to 2036 as biologic CDMOs digitize batch documentation.
• Broader country outlook: Canada expands at 6.4% yearly ahead of the United States at 6.2% and Switzerland at 6.1%. Meanwhile, France progresses at 5.7% annually over the ten-year window.

Market Size & Forecast

Table 1: Market Size and Forecast for the Electronic Lab Notebook Market (USD million and CAGR percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 586.0 million
Estimated Market Size in 2026	USD 624.1 million
Projected Market Size by 2036	USD 1,171.5 million
CAGR, 2026 to 2036	6.5%
Added Valuation, 2026 to 2036	USD 547.4 million

Strict regulatory inspections on laboratory data integrity are driving the adoption of electronic lab notebooks across drug development centers. Manual spreadsheet entry creates transcription errors and leaves raw chromatography files disconnected from experiment notes. According to July 2026 U.S. FDA data-integrity notifications, sponsors remain responsible for study reliability under ICH E6(R3) rules. Laboratory directors therefore link sample tracking software directly with electronic notebooks to verify every record.

Scientist-Pool and Experiment-Volume Sizing

Table 2: Scientist-Pool and Experiment-Volume Sizing for the Electronic Lab Notebook Market (USD million and operational ranges), 2025 to 2036

Metric	2025	2026	2036
Market size (USD million)	586.0	624.1	1,171.5
Active licensed ELN bench researchers (million seats)	1.05 to 1.18	1.12 to 1.25	1.95 to 2.20
Digital experiments documented per year (million records)	18.9 to 21.2	20.2 to 22.5	35.1 to 39.6
Annual software outlay per licensed scientist (USD)	496.6 to 558.1	499.3 to 557.2	532.5 to 600.8

Operational note: Scientist-pool ranges benchmark licensed R&D bench seats against multi-team institutional ELN rollout cohorts across active annual experiment creation rates.

Strong demand for clean machine-learning training data is propelling the adoption of structured cloud notebooks across biotechnology research centers. In addition to this, informatics teams connect electronic notebooks with plasmid registries so experimental data is ready for model training.

Per-Scientist & Research Facility Sizing

Table 3: Per Capita and Bench-Seat Allocation Indicators for the Electronic Lab Notebook Market (USD), 2025 to 2036

Metric	2025	2026	2036
World population (billion)	8.2	8.3	9.0
Market value per 1,000 people (USD)	71.5	75.2	130.2
Annual enterprise ELN site subscription (USD)	28,500.0 to 34,000.0	30,200.0 to 36,000.0	46,500.0 to 55,000.0
Cloud-native SaaS seat allocation (%)	66.5% to 68.5%	67.5% to 69.5%	78.0% to 82.0%

Table 4: Laboratory & Enterprise Seat Allocation Indicators for the Electronic Lab Notebook Market (USD and percentages), 2026

Metric	Value	Institutional Reference Basis
Market size, 2026	USD 624.1 million	2026 global valuation baseline
Active global R&D & QC laboratories	19,500 facilities	Global biopharma, chemical & academic ELN registry
Market value per laboratory	USD 32,005.1	Annualized enterprise & site license allocation
Biopharma, CRO & biotech allocation, 2026	USD 336.4 million	53.9% end-use industry segment allocation

Direct software links between analytical balances and HPLC machines with digital notebooks reduce manual entry errors in quality-control labs. Enterprise R&D groups pair electronic notebooks with connected diagnostic workflow systems to keep sample records accurate.

Analyst Perspective

"Enterprise R&D buyers no longer evaluate electronic lab notebooks as passive digital paper repositories for patent witnessing. Software vendors that embed structured ontology capture and native LIMS connectivity with governed AI design will win multi-year seat renewals."

- Sudip saha, Principal Consultant, Future Market Insights.

How is the electronic lab notebook market segmented?

The electronic lab notebook market is segmented by five primary commercial axes and region, covering functional scope, deployment model, license model, end-use industry, workflow integration, and region. In 2026, cross-disciplinary enterprise R&D ELN is projected at 57.1%, cloud-native multi-tenant and single-tenant SaaS at 68.7%, named-seat annual enterprise subscriptions at 76.3%, biopharmaceutical, CRO and biotech R&D at 53.9%, and LIMS and instrument data-capture integrated ELN at 64.2%.

By functional scope: Cross-disciplinary enterprise R&D ELN, specific biologics, chemistry and formulation ELN, quality control and analytical testing ELN, and others.

By deployment model: Cloud-native multi-tenant and single-tenant SaaS, on-premise validated GxP server, and hybrid private-cloud ELN.

By license model: Named-seat annual enterprise subscriptions, perpetual plus maintenance licenses, and academic and site-wide campus licenses.

By end-use industry: Biopharmaceutical, CRO and biotech R&D, chemical, petrochemical and materials science, food and beverage formulation and academic institutes, and others.

By workflow integration: LIMS and instrument data-capture integrated ELN, standalone protocol documentation ELN, AI-assisted reaction and sequence design ELN, and others.

Why does cross-disciplinary enterprise R&D ELN lead the functional scope category?

Based on functional scope, cross-disciplinary enterprise R&D ELN is projected to account for 57.1% in 2026, supported by unified schemas.

Table 5: Functional Scope Share for the Electronic Lab Notebook Market (percentage share), 2026

Functional Scope	Share (2026)
Cross-Disciplinary Enterprise R&D ELN	57.1%
Other Segments Combined	42.9%*
Total	100.0%

*Note: Other functional scope categories sum to 100.0% of 2026 electronic lab notebook demand.

Table 6: Functional Scope Leadership and Market Growth for the Electronic Lab Notebook Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	6.5%
Leading Segment	Cross-Disciplinary Enterprise R&D ELN

In the FMI report, large pharma companies prefer cross-disciplinary ELNs since chemists and biologists share one database without separate tools. Besides this, unified reaction tables and sequence maps inside one workspace support automated laboratory informatics across discovery teams.

• Within functional scope, cross-disciplinary enterprise R&D ELN solutions will claim 57.1% during 2026 by unifying small-molecule and biologics workflows.
• According to an August 2026 PLoS One rollout study at University Medicine Halle, 237 users across 32 teams created 4,263 experiments.

What supports cloud-native SaaS as a preferred choice in deployment models?

By deployment model, cloud-native SaaS architectures are estimated to hold 68.7% in 2026, driven by continuous GxP cloud validation.

Lower IT maintenance costs and faster validation updates are driving the adoption of cloud-native SaaS notebooks across research laboratories. External sponsors and contract research labs share assay results through cloud workspaces linked to regulated clinical trial repositories without local server delays.

• Cloud-native multi-tenant and single-tenant SaaS deployments command an estimated 68.7% of deployment model demand during 2026 via vendor hosting.
• For instance, a June 2025 study in ADMET and DMPK designed katG guide RNAs using the Benchling cloud CRISPR tool.

How are named-seat annual enterprise subscriptions gaining use in license models?

In 2026, named-seat annual enterprise subscriptions are expected to lead license model with 76.3% share, owing to multi-year SaaS contracting.

Predictable annual budgeting and automatic software upgrades are propelling the demand for named-seat annual enterprise subscriptions across R&D buyers. Procurement teams scale user seat counts easily as drug discovery projects move into genomic variant interpretation pipelines and preclinical testing.

• Named-seat annual enterprise subscriptions concentrate an expected 76.3% of license model value during 2026 as SaaS vendors retire perpetual licensing.
• In December 2025, Dassault Systèmes Technical Note T75-2025 for BIOVIA Notebook 2026 detailed ChemDraw 25 and SnapGene 8.1 desktop connectors.

Why are buyers selecting biopharmaceutical and biotech R&D in end-use industry?

By end-use industry, biopharmaceutical, CRO and biotech R&D is forecast to represent 53.9% in 2026, enabled by Part 11 rules.

High experiment volumes and strict electronic signature rules for new drug filings drive heavy notebook adoption in biopharmaceutical R&D labs. Unlike academic or food testing labs, pharmaceutical sponsors audit external contract labs on digital record security before awarding study contracts.

• Biopharmaceutical, CRO and biotech R&D accounts generate a forecast 53.9% of end-use industry demand during 2026 under submission rules.
• According to an August 2026 Bristol Myers Squibb study in ACS Organic & Inorganic Au, Katalyst D2D ELN speeded amidation optimization.

Which market conditions keep LIMS-integrated ELN ahead within workflow integration?

LIMS and instrument data-capture integrated ELN is likely to capture 64.2% share in 2026, reinforced by automated chromatography capture.

Strong need to eliminate manual typing of balance weights and chromatography results supports demand for LIMS-integrated electronic lab notebooks. Direct links between notebook pages and LIMS sample IDs ensure analysts follow every required step during quality testing.

• LIMS and instrument data-capture integrated ELN solutions secure an anticipated 64.2% of workflow integration value during 2026.
• According to a May 2026 BMJ Innovations study, integrating Malawi's national LIMS with electronic medical records cut turnaround by 65 days.

What are the drivers, restraints, and opportunities in the electronic lab notebook market?

In the electronic lab notebook market, the key driver is Part 11 compliance, the key restraint is rigid templates, and the key opportunity is agentic AI co-scientists.

• Driver: Strict FDA and EMA electronic data-integrity inspections and FAIR machine-learning data readiness mandates push R&D labs to replace paper and spreadsheets.
• Restraint: Proprietary file formats across legacy ELN vendors and time-consuming template customization frustrate bench scientists and trigger unauthorized shadow AI usage.
• Opportunity: Governed agentic AI co-scientists for retrosynthesis and codon optimization with Python API data bridges open higher per-seat subscription tiers.

Growth Analysis and Qualitative Demand Drivers

Strict regulatory inspections against unverified testing data and manual spreadsheet logs are driving the demand for electronic lab notebooks. Pharmaceutical companies also need structured, machine-readable experiment records to train internal artificial intelligence models for drug discovery. As per FMI, connecting wet-lab notebooks with robotic liquid handling workcells removes manual data entry bottlenecks across screening laboratories. For instance, in June 2026, the U.S. FDA rejected premarket submissions from three third-party testing labs over falsified study records. Agency inspectors found missing instrument audit trails and unverified spreadsheet edits across rejected bioanalytical study dossiers. Drug sponsors therefore require timestamped electronic lab notebook records across internal and contracted laboratories before approving study milestones.

Usability and Schema Interoperability Risk Assessment

Rigid second-generation notebook templates and incompatible vendor file formats are major restraining factors that hamper wider electronic lab notebook adoption. When scientists must use manual CSV files or custom scripts to move data between chemistry and biology tools, work slows down. According to the January 2026 Sapio Sciences survey of 150 scientists, only 7% could modify ELN workflows without IT help. Nearly 95% of surveyed researchers reported that existing notebooks made multi-experiment data analysis difficult across active projects. Laboratories managing sequencing library quality controls also face high switching costs when moving historical archives between competing cloud vendors. Enterprise buyers therefore demand open data export tools before signing multi-year software renewals.

Commercial Opportunity in Governed Agentic AI

Strong scientist demand for built-in data interpretation and experiment design tools is creating new growth opportunities for notebook software vendors. In the January 2026 Sapio Sciences study, 96% of surveyed scientists stated future ELNs must help interpret experimental results. Vendors embedding governed reaction planning with mass spectrometry protein workflows inside compliant notebooks prevent unauthorized shadow AI use. For instance, in January 2026, Sygnature Discovery showed in SLAS Technology that FAIR notebook protocols helped chemists score synthetic routes. Structured reaction capture allowed automated machine-learning models to rank synthesis options directly inside the electronic notebook workspace. Open Python API connectors further help software vendors expand seat licenses across large pharmaceutical accounts.

Electronic Lab Notebook Market by Country (2026 to 2036)

As per the analysis from FMI, South Korea advances at 7.6% annually in electronic lab notebooks until 2036. Conversely, France progresses at 5.7% per year across the ten-year forecast horizon. Country-level growth across East Asia and Western markets tracks biopharmaceutical CDMO capacity and national FAIR research data mandates.

Table 7: Country CAGR and Primary Growth Levers for the Electronic Lab Notebook Market (CAGR percentage and operational drivers), 2026 to 2036

Country	CAGR (2026 to 2036)	Primary Growth Lever
South Korea	7.6%	Biologics CDMO expansion in Songdo and FDA 21 CFR Part 11 cloud batch documentation
Canada	6.4%	Laboratories Canada federal science modernization and Toronto-Montreal AI biotech discovery hubs
USA	6.2%	Agentic AI co-scientist upgrades, NIH FAIR mandates, and Python API workflow automation
Switzerland	6.1%	Multinational pharma ontology harmonization and sovereign single-tenant cloud standardization
UK	6.0%	Golden Triangle biotech CRO digitalization and cryptographic FAIR research reproducibility
Germany	5.9%	NFDI research data interoperability and Python API bridges across chemistry and materials labs
Japan	5.8%	PMDA electronic submission readiness and chemical materials-informatics AI pipeline creation
France	5.7%	Unified AI life-sciences platform adoption across pharmaceutical and cosmetics formulation R&D

Source: Future Market Insights analysis

South Korea Electronic Lab Notebook Market Outlook (2026 to 2036)

Rapid expansion of biologics contract manufacturing facilities in Songdo and Daejeon is driving enterprise cloud ELN adoption across South Korea. Korean biopharma companies are replacing paper batch binders with 21 CFR Part 11 digital workspaces to pass U.S. FDA inspections. For instance, in September 2025, Sapio Sciences launched its 3rd-generation agentic AI Sapio ELN with codon optimization for CROs. By 2036, South Korea is projected to grow at 7.6% CAGR, driven by biologics CDMO expansion and automated batch documentation. However, strict Korean data privacy laws and local language interface requirements create hurdles for foreign software vendors. Global informatics suppliers therefore partner with Seoul IT integrators to provide Korean user interfaces and local cloud hosting.

Key takeaway: In South Korea, export-oriented biologics CDMO expansion and FDA inspection readiness will support 7.6% yearly growth to 2036.

Canada Electronic Lab Notebook Market Outlook (2026 to 2036)

Fragmented legacy laboratory databases across provincial health institutes and university biotech incubators in Toronto and Montreal complicate cross-site data sharing. Government and academic research centers are upgrading to unified cloud notebooks so multi-site teams can share experimental protocols securely. According to an August 2026 Public Services and Procurement Canada release, Laboratories Canada is modernizing facilities for 275 federal scientists. The modernized federal campus unites 25 public-health and border-security science programs on repeatable digital research infrastructure. Canada's electronic lab notebook outlook is anticipated to advance at 6.4% CAGR through 2036, supported by federal laboratory modernization. Strict provincial data-residency rules still require vendors to host public-sector notebooks on Canadian cloud servers in Montreal and Toronto.

Key takeaway: In Canada, federal Laboratories Canada modernization and AI drug-discovery cluster expansion are anticipated to support a 6.4% CAGR.

USA Electronic Lab Notebook Market Outlook (2026 to 2036)

United States demand is anchored by Boston and San Francisco biopharma clusters upgrading legacy notebooks to AI-enabled cloud platforms. High manual data-import friction across 81% of surveyed U.S. scientists drives enterprise replacement of older second-generation electronic notebooks. According to a September 2026 bioRxiv study by NIH and university researchers, the labapi Python tool automated LabArchives ELN workflows. Electronic lab notebook demand in the USA is forecast to rise at 6.2% CAGR through 2036, owing to NIST AI governance. However, high multi-year migration costs across thousands of legacy chemistry seats still lengthen pharmaceutical procurement cycles. Software vendors therefore provide automated legacy-archive migration scripts and pre-validated GxP connectors to speed enterprise rollouts.

Key takeaway: In the USA, AI-ready cloud notebook migrations and automated Python API instrument pipelines will sustain 6.2% yearly expansion.

Switzerland Electronic Lab Notebook Market Outlook (2026 to 2036)

Global pharmaceutical headquarters and fine-chemical research centers in Basel and Zurich drive demand for multi-site ELN ontology standardization in Switzerland. Swiss enterprise informatics teams prioritize single-tenant sovereign cloud hosting and automated metadata capture to train internal machine-learning discovery models. For instance, in February 2026, Revvity reported USD 2,856 million in 2025 collections with USD 1,431 million in Life Sciences. Adoption of electronic lab notebooks in Switzerland is estimated to expand at 6.1% CAGR through 2036, enabled by multinational pharma ontology standardization. High baseline ELN seat penetration across large Basel pharmaceutical campuses limits first-time user additions across domestic labs. Informatics vendors therefore expand account value by upselling agentic AI design modules and automated high-throughput experimentation links.

Key takeaway: In Switzerland, multinational pharma ontology standardization and sovereign single-tenant SaaS upgrades will keep annual growth at 6.1%.

UK Electronic Lab Notebook Market Outlook (2026 to 2036)

Golden Triangle biotechnology ventures across Cambridge and Oxford face strict MHRA GxP data-integrity audits during preclinical candidate handoffs. Contract research organizations and university spin-outs are adopting cloud-native electronic notebooks to document assay reproducibility for pharmaceutical licensing partners. According to a May 2026 King's College London study in Frontiers in Neuroinformatics, IntegriLAB certified neuroimaging reproducibility using blockchain timestamps. Earlier in June 2025, University of Nottingham researchers validated the open-source AI4Green4Students ELN in Journal of Chemical Education for sustainable synthesis. The UK electronic lab notebook sector is projected to record 6.0% CAGR through 2036, reinforced by CRO digitalization and green-chemistry metrics. Tight university department budgets still restrain per-seat pricing, so vendors offer discounted campus site licenses.

Key takeaway: In the UK, Golden Triangle CRO digitalization and cryptographic FAIR reproducibility frameworks are projected to support a 6.0% annual growth rate.

Germany Electronic Lab Notebook Market Outlook (2026 to 2036)

Germany's National Research Data Infrastructure consortia and specialty chemical producers in Ludwigshafen make API interoperability and GDPR residency top procurement gates. Enterprise chemical and materials laboratories require bidirectional links between synthesis notebooks and automated spectroscopy and imaging repositories. For instance, in May 2025, Karlsruhe Institute of Technology researchers published ELNdataBridge in Journal of Cheminformatics to link Chemotion ELN via Python. According to an August 2026 Scientific Data study from Greifswald, linking eLabFTW with OMERO achieved 60% FAIR bioimaging compliance. In Germany, electronic lab notebook demand is predicted to advance at 5.9% CAGR through 2036, supported by NFDI interoperability standards. Strict German works-council reviews of employee timestamp monitoring still require configurable privacy controls.

Key takeaway: In Germany, NFDI interoperability standards and chemical-materials API bridges will support 5.9% yearly expansion to 2036.

Japan Electronic Lab Notebook Market Outlook (2026 to 2036)

Japanese pharmaceutical innovators in Osaka and Tokyo with electronic-materials formulators are expanding cloud ELN adoption for PMDA submission audits. Domestic R&D groups historically favored on-premise servers, yet global co-development partnerships with U.S. biotechs now require shared cloud workspaces. According to a January 2026 AgBioData consortium study in Database, standardized FAIR data frameworks now govern over 40 genomic repositories. Japan is estimated to post 5.8% CAGR over the forecast period, influenced by PMDA electronic data-integrity inspections and materials-informatics AI pipelines. Custom legacy LIMS interfaces and double-byte Kanji chemical nomenclature indexing still complicate off-the-shelf software rollouts across domestic factories. Global ELN vendors therefore maintain dedicated Tokyo validation engineers and pre-configured Japanese regulatory templates.

Key takeaway: In Japan, PMDA electronic audit compliance and materials-informatics training pipelines will support 5.8% annual progression to 2036.

France Electronic Lab Notebook Market Outlook (2026 to 2036)

French pharmaceutical and cosmetics-formulation laboratories confront fragmented data silos across discovery chemistry and regulatory dossier preparation teams. R&D directors in Paris and Lyon are consolidating separate bench notebooks and clinical trial repositories onto unified AI-enabled software platforms. For instance, in October 2026, Dassault Systèmes completed its USD 1,800 million ArisGlobal acquisition to unite BIOVIA and MEDIDATA on one platform. Earlier in August 2025, a European review in Analytical and Bioanalytical Chemistry showed automated digital workflows resolve biologics characterization bottlenecks. Electronic lab notebook demand in France is forecast to expand at 5.7% CAGR by 2036, associated with platform consolidation. Strict SecNumCloud sovereign cloud preferences across French public research institutes lengthen procurement reviews and favor domestic cloud-certified scientific informatics suites.

Key takeaway: In France, unified AI life-sciences platform consolidation across biopharma and cosmetics R&D is forecast to support a 5.7% CAGR.

Full report country CAGRs cover: North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.

Who are the notable companies in the electronic lab notebook market?

Revvity, Inc., Dassault Systèmes SE, Benchling, Inc., LabWare, Inc., Thermo Fisher Scientific Inc., Sapio Sciences, LLC, Agilent Technologies, Inc., and Waters Corporation are the notable companies in the electronic lab notebook market.

FMI data suggests that the electronic lab notebook market divides between enterprise scientific-informatics leaders and cloud-native biotech R&D platforms. Dedicated SaaS providers win high-growth biologics and medicinal chemistry accounts through intuitive sequence and stoichiometry editors with governed AI assistants. Diversified analytical instrument and LIMS corporations capture regulated quality-control and process-development laboratories by bundling ELN modules directly with chromatography data systems.

• Enterprise Scientific-Informatics Suites: Revvity (Signals Notebook) and Dassault Systèmes (BIOVIA Notebook) supply multi-disciplinary chemistry and biologics cloud notebooks across global pharma.
• Cloud-Native Biopharma & Agentic AI Platforms: Benchling and Sapio Sciences deliver cloud-native molecular biology registries and unified LIMS-ELN workspaces with agentic AI co-scientist tools.
• LIMS & Analytical-Instrument Integrated Vendors: LabWare and Thermo Fisher Scientific with Agilent Technologies and Waters Corporation integrate procedural ELNs with LIMS and chromatography systems.

Competitive Benchmarking: Electronic Lab Notebook Market

Table 8: Competitive Benchmarking for the Electronic Lab Notebook Market (qualitative capability ratings), 2026

Company	Cross-Disciplinary R&D Breadth	Cloud SaaS & AI Depth	LIMS & Instrument Integration	Geographic Reach
Revvity, Inc.	High	High	High	High
Dassault Systèmes SE	High	High	High	High
Benchling, Inc.	High	High	Medium	High
LabWare, Inc.	Medium	Medium	High	High
Thermo Fisher Scientific Inc.	High	Medium	High	High
Sapio Sciences, LLC	High	High	High	Medium
Agilent Technologies, Inc.	Medium	Medium	High	High
Waters Corporation	Medium	Medium	High	High

Scoring basis: Capability tiers evaluate documented small-molecule stoichiometry and biologics sequence registration depth with native LIMS and chromatography instrument connectivity. Cloud GxP compliance and geographic ratings reflect ISO/IEC 27001 and 21 CFR Part 11 validation packages across enterprise pharma deployments.

Key Developments in the Electronic Lab Notebook Market

• In October 2026, Dassault Systèmes completed the USD 1,800 million acquisition of ArisGlobal to unite BIOVIA and MEDIDATA.
• In August 2026, Revvity reported USD 730 million in second-quarter 2026 collections after USD 2,856 million in 2025 collections.
• In September 2025, Sapio Sciences launched its 3rd-generation agentic AI Sapio ELN before publishing its 150-scientist study in January 2026.

Key Players in the Electronic Lab Notebook Market

Enterprise Multi-Disciplinary Scientific Informatics Leaders

• Revvity, Inc.
• Dassault Systèmes SE
• Thermo Fisher Scientific Inc.

Cloud-Native Biopharma and Agentic AI Notebook Platforms

• Benchling, Inc.
• Sapio Sciences, LLC
• LabWare, Inc.

Analytical Instrument and Chromatography-Integrated ELN Providers

• Agilent Technologies, Inc.
• Waters Corporation

Electronic Lab Notebook Market Report Scope

Table 9: Report Scope for the Electronic Lab Notebook Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Functional Scope; Deployment Model; License Model; End-Use Industry; Workflow Integration
Quantitative Units	USD Million
Market Definition	Includes commercial supplier license, SaaS subscription, and implementation valuation from electronic lab notebook software across R&D, formulation, and quality-control laboratories. Category Scope Note: Excludes standalone LIMS licenses sold without ELN modules, standalone chromatography hardware, and general office word-processing suites.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	South Korea, Canada, USA, Switzerland, UK, Germany, Japan, France, and additional countries in the full report
Key Companies Covered	Revvity, Inc., Dassault Systèmes SE, Benchling, Inc., LabWare, Inc., Thermo Fisher Scientific Inc., Sapio Sciences, LLC, Agilent Technologies, Inc., Waters Corporation
Forecast Period	2026 to 2036
Approach	Primary and secondary research with top-down and bottom-up market triangulation.

Electronic Lab Notebook Market Research Methodology

Table 10: Research Methodology for the Electronic Lab Notebook Market (research methods and approach), 2026 edition

Method	Approach
Primary Research	Primary interviews were conducted with pharmaceutical R&D IT directors, medicinal chemistry and biologics lab heads, QA/QC data-integrity officers, and laboratory informatics integrators across the value chain to validate software trends, ontology standards, demand dynamics, and licensing decisions.
Secondary Research	Secondary research included company annual reports, investor presentations, FDA and EMA data-integrity publications, NIST AI governance standards, peer-reviewed cheminformatics journals, company websites, product literature, and other publicly available sources relevant to the market.
Market Sizing and Forecasting	Market sizing and forecasting for the 2026 to 2036 forecast period were developed using top-down and bottom-up approaches to assess licensed bench scientist seats, SaaS subscription tiers, and enterprise adoption trends.
Country Forecasting Model	Econometric national projections weight biopharmaceutical R&D headcount, CDMO facility capacity, and national research data interoperability mandates across eight evaluated countries.
Operational Benchmark Traceability	Scientist-pool and seat-allocation indicators in Tables 2, 3, and 4 trace to university and biopharma ELN rollout cohorts, Sapio Sciences industry surveys, and corporate seat disclosures.
Data Triangulation and Validation	Data is validated against macro-economic indicators, R&D informatics adoption drivers, regulatory data-integrity frameworks, and historical trend analysis to ensure high accuracy without double counting adjacent categories.

Electronic Lab Notebook Market by Segments

Electronic Lab Notebook Market segmented by Functional Scope:

• Cross-Disciplinary Enterprise R&D ELN
• Specific Biologics, Chemistry & Formulation ELN
• Quality Control & Analytical Testing ELN
• Others

Electronic Lab Notebook Market segmented by Deployment Model:

• Cloud-Native Multi-Tenant & Single-Tenant SaaS
• On-Premise Validated GxP Server
• Hybrid Private-Cloud ELN

Electronic Lab Notebook Market segmented by License Model:

• Named-Seat Annual Enterprise Subscriptions
• Perpetual + Maintenance Licenses
• Academic & Site-Wide Campus Licenses

Electronic Lab Notebook Market segmented by End-Use Industry:

• Biopharmaceutical, CRO & Biotech R&D
• Chemical, Petrochemical & Materials Science
• Food & Beverage Formulation & Academic Institutes
• Others

Electronic Lab Notebook Market segmented by Workflow Integration:

• LIMS & Instrument Data-Capture Integrated ELN
• Standalone Protocol Documentation ELN
• AI-Assisted Reaction & Sequence Design ELN
• Semantic Ontology & FAIR Data-Bridge ELN
• Others

Electronic Lab Notebook Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • Taiwan
  • Japan
  • South Korea
• South Asia and Pacific
  • Singapore
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Sapio Sciences, LLC. (2026, January 27). Research finds scientists view ELNs as glorified filing cabinets, driving frustration, duplication and shadow AI use. Sapio Sciences Newsroom.
• [2] United States Food and Drug Administration. (2026, July 14). Notifications on Data Integrity: Drug Safety and Availability. U.S. Department of Health and Human Services, FDA CDER.
• [3] Jäger, C., Zagrodnick, M., Schwede, B., & Christoph, J. (2026, August 20). Digital transformation in laboratory documentation: Insights from an eLabFTW case study and a survey-informed onboarding framework. PLoS One, 21(8), e0355558 (PubMed PMID 42623395).
• [4] Wulandari, D. A., Zein, M. I. H. L., Zakiyyah, S. N., Ishmayana, S., Ozsoz, M., Hartati, Y. W., & Irkham. (2025, June 17). CRISPR-Cas9-based electrochemical biosensor for the detection of katG gene mutations in isoniazid-resistant tuberculosis. ADMET and DMPK, 13(3), 2766 (PubMed PMID 40585408).
• [5] Dassault Systèmes SE. (2025, December 12). T75-2025: Notification regarding BIOVIA Notebook 2026 Release and Enhancements. Dassault Systèmes Documentation.
• [6] Stevens, J. M., Golden, D. L., Dare, N., Aggarwal, S., Del Valle, D., DiSomma, S., et al. (2026, August 17). Structured HTE Data and Integrated Bayesian Optimization Accelerate Scalable Amidation Process Development. ACS Organic & Inorganic Au, 6(5), 624-635 (PubMed PMID 42857042).
• [7] Chapuma, C., Bondwe, P., Singini, G., Chamanga, R., Nkosi, P., Ghobede, E., & Maphosa, T. (2026, May 21). Potential of integrated national laboratory information management system in enhancing early HIV care for infants in Malawi: a report. BMJ Innovations, bmjinnov-2025-001428 (PubMed PMID 42466118).
• [8] United States Food and Drug Administration. (2026, June 25). Notifications on Data Integrity: Medical Devices. U.S. Department of Health and Human Services, FDA CDRH.
• [9] Qin, T., Chandrasekaran, A., Hoffman, J., Shiers, J., Jain, T., & Sambrook Smith, C. (2026, January 31). Empowering chemists in drug design: Delivering AI solutions through an ELN framework at the enterprise level. SLAS Technology, 37, 100392 (PubMed PMID 41628711).
• [10] Sapio Sciences, LLC. (2025, September 16). Sapio Sciences Introduces World's First 3rd-Generation ELN. Sapio Sciences Newsroom.
• [11] Public Services and Procurement Canada. (2026, August 12). Government of Canada advances major infrastructure project to strengthen public and animal health, border protection and security science. Government of Canada.
• [12] Li, C., Lawrimore, J., Moraczewski, D., & Thomas, A. G. (2026, September 7). labapi: a Python object model for the LabArchives electronic lab notebook. bioRxiv, 2026.09.02.748406 (PubMed PMID 42818661).
• [13] National Institute of Standards and Technology. (2026, April 7). AI Risk Management Framework and Trustworthy AI Profile Updates. U.S. Department of Commerce, NIST Information Technology Laboratory.
• [14] Revvity, Inc. (2026, February 2). Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025. Revvity Investor Relations.
• [15] Easmin, R., Veronese, M., Allen, P., Nordio, G., & Turkheimer, F. (2026, May 21). IntegriLAB: a blockchain-enabled electronic lab notebook for reproducible neuroimaging research. Frontiers in Neuroinformatics, 20, 1753937 (PubMed PMID 42255115).
• [16] Nwafor, P. C., Gurung, S., van Krimpen, P., Schnaubert, L., Jolley, K., Pearman-Kanza, S., Willoughby, C., & Hirst, J. D. (2025, June 5). AI4Green4Students: Promoting Sustainable Chemistry in Undergraduate Laboratories with an Electronic Lab Notebook. Journal of Chemical Education, 102(7), 2720-2731 (PubMed PMID 40655192).
• [17] Starman, M., Kirchner, F., Held, M., Eschke, C., Sahim, S.-A., Willumeit-Römer, R., Jung, N., & Bräse, S. (2025, May 26). ELNdataBridge: facilitating data exchange and collaboration by linking Electronic Lab Notebooks via API. Journal of Cheminformatics, 17(1), 86 (PubMed PMID 40420243).
• [18] Ahmadi, M., Wagner, R., Bekeschus, S., & Becker, M. M. (2026, August 4). Data Management Workflow for FAIR Sharing of Bioimaging Datasets in Plasma Medicine. Scientific Data, 13(1), 1124 (PubMed PMID 42552320).
• [19] Marrano, A., Andorf, C., Campbell, J. D., Cannon, E., Coe, M., Cooper, L., et al. (2026, January 15). The future is FAIR: a community framework for enhanced data management and data sharing. Database (Oxford), 2026, baag058 (PubMed PMID 42788682).
• [20] Dassault Systèmes SE. (2026, October 28). Dassault Systèmes Takes Its Life Sciences Ambition to the Next Level with a Unified AI Platform Connecting Science, Medicine and Patients. Dassault Systèmes Newsroom.
• [21] Cunha, D. R., Quinaz, M. B., & Segundo, M. A. (2025, August 12). Biopharmaceutical analysis: current analytical challenges, limitations, and perspectives. Analytical and Bioanalytical Chemistry, 418(2), 373-394 (PubMed PMID 40790361).
• [22] Revvity, Inc. (2026, August 4). Revvity Announces Financial Results for the Second Quarter of 2026. Revvity Investor Relations.
• [23] Liu, J., Pandya, S., Coppi, A., Young, H. P., Krumholz, H. M., Schulz, W. L., & Gong, G. (2026, January 9). Assessment of the integrity of real-time electronic health record data used in clinical research. PLoS One, 21(1), e0340287 (PubMed PMID 41511976).

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the electronic lab notebook market in 2026 and 2036?
• Which data-integrity and AI-readiness pressures support electronic lab notebook demand?
• Why does cross-disciplinary enterprise R&D ELN lead the functional scope category?
• Why does cloud-native multi-tenant and single-tenant SaaS lead deployment models?
• How do growth rates differ across South Korea, Canada, the USA, and Switzerland?
• Which notable companies supply enterprise R&D and LIMS-integrated ELN platforms today?
• What limits adoption or supplier switching in the electronic lab notebook market?
• What should R&D IT buyers evaluate before licensing an electronic lab notebook?